Learning Health Systems as Facilitators of Precision Medicine

The concept of the learning health system offers promise to facilitate personalized medicine. In children, serious illness is uncommon so generating and applying new knowledge therefore requires networks of institutions. To illustrate the concept of the Learning Health System, we describe the example of the ImproveCareNow Network. We then use a network case study to illustrate how the concept of precision medicine can be achieved through a Learning Health System in a real-world clinical environment.

[1]  D. Mould,et al.  Clinical Decision Support Tools: The Evolution of a Revolution , 2016, Clinical pharmacology and therapeutics.

[2]  E. Seidman,et al.  Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease , 2016, Therapeutic advances in gastroenterology.

[3]  R. Saunders,et al.  COMMITTEE ON THE LEARNING HEALTH CARE SYSTEM IN AMERICA , 2013 .

[4]  V. V. D. van der Velden,et al.  Monitoring Antigen-Specific Biologics: Current Knowledge and Future Prospects , 2013, Therapeutic drug monitoring.

[5]  V. Chandra-Mouli,et al.  Translating evidence into action , 2017 .

[6]  A. Pérez‐Pitarch,et al.  A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients. , 2015, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[7]  A. Griffiths,et al.  Intercenter variation in initial management of children with Crohn's disease , 2007, Inflammatory bowel diseases.

[8]  R. Saunders,et al.  Best Care at Lower Cost: The Path to Continuously Learning Health Care in America , 2013 .

[9]  G. D'Haens,et al.  The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease , 2015, Scandinavian journal of gastroenterology.

[10]  A. Abernethy.  Demonstrating the Learning Health System Through Practical Use Cases , 2014, Pediatrics.

[11]  T. Shimosegawa,et al.  Inflammatory Bowel Disease (IBD) , 2013 .

[12]  K. Van Steen,et al.  Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. , 2015, Gastroenterology.

[13]  Kryshkina Vp,et al.  [Complex hybrids of mouse line CBWA--a new model for biomedical research]. , 1972 .

[14]  Mache Creeger,et al.  Evolution or Revolution? , 2006, ACM Queue.

[15]  J. Markowitz,et al.  Consensus and Controversy in the Management of Pediatric Crohn Disease: An International Survey , 2003, Journal of pediatric gastroenterology and nutrition.

[16]  Keith Marsolo,et al.  Effectiveness of Anti-TNFα for Crohn Disease: Research in a Pediatric Learning Health System , 2014, Pediatrics.

[17]  S. Targan,et al.  Differences in the management of Crohn’s disease among experts and community providers, based on a national survey of sample case vignettes , 2007, Alimentary pharmacology & therapeutics.

[18]  D. Mould.  Why therapeutic drug monitoring is needed for monoclonal antibodies and how do we implement this? , 2016, Clinical pharmacology and therapeutics.

[19]  J. Barrett.  Paediatric models in motion: requirements for model‐based decision support at the bedside , 2015, British journal of clinical pharmacology.

[20]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[21]  Muin J Khoury,et al.  Convergence of Implementation Science, Precision Medicine, and the Learning Health Care System: A New Model for Biomedical Research. , 2016, JAMA.

[22]  Brian T. Austin,et al.  Organizing care for patients with chronic illness. , 1996, The Milbank quarterly.

[23]  R. Shamir,et al.  Practice Variations in the Management of Inflammatory Bowel Disease Between Pediatric and Adult Gastroenterologists , 2016, Journal of pediatric gastroenterology and nutrition.

[24]  Thomas Bodenheimer,et al.  Improving primary care for patients with chronic illness. , 2002, JAMA.

[25]  E H Wagner,et al.  Chronic disease management: what will it take to improve care for chronic illness? , 1998, Effective clinical practice : ECP.

[26]  Paul W G Elbers,et al.  Right dose, right now: using big data to optimize antibiotic dosing in the critically ill. , 2014, Anaesthesiology intensive therapy.

[27]  K. Movig,et al.  Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF‐α experience to oncology , 2016, Clinical pharmacology and therapeutics.

[28]  P. Margolis,et al.  Improved Outcomes in a Quality Improvement Collaborative for Pediatric Inflammatory Bowel Disease , 2012, Pediatrics.

[29]  Honghui Zhou,et al.  Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. , 2011, Clinical therapeutics.

[30]  P. Banks,et al.  Are Patients with Inflammatory Bowel Disease Receiving Optimal Care? , 2005, The American Journal of Gastroenterology.

[31]  Peter Margolis,et al.  ImproveCareNow: The development of a pediatric inflammatory bowel disease improvement network , 2011, Inflammatory bowel diseases.

[32]  Brian T. Austin,et al.  Improving chronic illness care: translating evidence into action. , 2001, Health affairs.

[33]  Keith Marsolo,et al.  A Digital Architecture for a Network-Based Learning Health System: Integrating Chronic Care Management, Quality Improvement, and Research , 2015, EGEMS.

[34]  David C Wilson,et al.  Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification , 2011, Inflammatory bowel diseases.

[35]  Øystein D. Fjeldstad,et al.  The architecture of collaboration , 2012 .

[36]  Olivia Carter-Pokras,et al.  Prescribing Patterns and Awareness of Adverse Effects of Infliximab: A Health Survey of Gastroenterologists , 2007, Digestive Diseases and Sciences.

[37]  Michael Seid,et al.  Coproduction of healthcare service , 2015, BMJ Quality & Safety.

[38]  R. Leong,et al.  Proteomics and metabolomics in inflammatory bowel disease , 2013, Journal of gastroenterology and hepatology.

[39]  Thomas Bodenheimer,et al.  Improving primary care for patients with chronic illness: the chronic care model, Part 2. , 2002, JAMA.

[40]  R. Baldassano,et al.  Variation in Care in Pediatric Crohn Disease , 2009, Journal of pediatric gastroenterology and nutrition.

[41]  Matthias Schroder,et al.  The Learning Healthcare System Workshop Summary , 2016 .

[42]  M. Dubinsky,et al.  Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies , 2015, Journal of clinical pharmacology.

[43]  K. Kolho,et al.  Serum infliximab concentrations in pediatric inflammatory bowel disease , 2013, Scandinavian journal of gastroenterology.

[44]  A. Barton,et al.  The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases , 2013, Rheumatology.

[45]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.